Actavis plant addition to create 220 jobs; Strides CEO sees growth in biologics after Agila deal;

@FiercePharma: Interesting look at Big Pharma's new-drug sales, a.k.a Freshness Index, from Forbes columnist Bernard Munos. Report | Follow @FiercePharma

@EricPFierce: Actavis getting nearly $3 million from taxpayers to expand a plant in Florida. Story | Follow @EricPFierce

> Actavis plans to invest $40.5 million into its plant in Davie, FL, in an expansion expected to create about 220 new jobs. Report

> Strides Arcolab CEO Arun Kumar figures the Indian company can beef up its biologics business and pharma sales to quickly replace revenues from its to-be-sold injectables unit Agila Specialties. Report

> Indian generics makers Lupin and Aurobindo Pharma won FDA approval for their versions of Diovan HCT, a combination blood-pressure pill made by Novartis ($NVS). Report

> The FDA approved Cangene's Botulism Antitoxin Heptavalent, the first antibody to combat all types of toxins known to cause botulism. Report

> China's Sinopharm says its 2012 profits are up 26% from 2011, at 1.97 billion yuan ($317 million). Report

> Indian pharmaceutical exports to Nigeria rose to $307 million for the most recent fiscal year, an increase of 35% over the previous year. Report

Medical Device News

 @FierceMedDev: Cornell: Metal stents work well as blocked bile duct treatment. Item | Follow @FierceMedDev

 @MarkHFierce: Third Rock is rolling out a new $516M VC fund, for device, Dx and biotech companies. Target: early-stage companies. Release | Follow @MarkHFierce

 @DamianFierce: Abbott is warning overseas surgeons about a safety issue with MitraClip, all as it seeks FDA approval. Report | Follow @DamianFierce

> Ohio company pulls in $9M Series B for laparoscopic visual shield. Story

> Argon puts $362.5M on Angiotech's interventionals biz. Article

> Prostate cancer patients driving penile implant boom. Report

Biotech News

 @FierceBiotech: More on CRO shutdown from FierceCRO.com: Former Cetero shutters ops, leaving sponsors, patients locked out. Story | Follow @FierceBiotech

@JohnCFierce: Third Rock Ventures adds $516M fund to back new portfolio of biotechs. News | Follow @JohnCFierce

@RyanMFierce: Astellas Pharma taps supercomputer for IT-driven drug discovery. More | Follow @RyanMFierce

> Versant adds $7.5M to upstart biotech's A round. Story

> Strike two: FDA hands United Therapeutics another rejection on oral Remodulin. Article

> Novartis snags FDA approval for antibiotic in CF patients. Story

CRO News

> Bayer deepens Cambodian presence with DKSH partnership. More

> Sanofi beefs up CMO game with Transgene deal. Item

> Dr. Reddy's wins $22.5M from CRO Nordion. News

> Duke's in-house CRO snags trial deal for RNAi drug. Article

> ShangPharma wins investor vote for go-private plan. Story

Biotech IT News

> BlackBerry founder bets on quantum tech in life sciences. Item

> NextDocs and Microsoft pushing clinical trials to the cloud. Story

> AstraZeneca IT chief talks up Big Data amid R&D turmoil. Report

> Biotech data merges onto UC San Diego's Big Data 'freeway.' Article

> Merck slashes data-management costs with China site. More

And Finally... The American Academy of Neurology said about 20% of surveyed members missed major FDA safety warnings on antiepileptic medicines. Report

Suggested Articles

AstraZeneca and Brazil have expanded their deal for a possible COVID-19 vaccine, this time to the tune of $360 million.

Novavax expects to churn out enough vaccines in 2021 to meet U.S. demand; experts slam the medical and political risks of Russia's unproven vaccine.

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.